News

Gene therapy enters the eye
Enlarge image

BusinessFranceSwitzerlandUK

Gene therapy enters the eye

09.04.2013 - A new French start-up secured a seed financing of €32m. Based on an optogenetics/gene therapy approach, it aims to cure eye diseases.

The field of gene therapies is experiencing a serious tailwind these days. On 8 April, GenSight Biologics announced the closure of a €32m Series A financing. The Parisian biopharmaceutical company works on the development of ophthalmic therapeutics – using gene therapy. The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

The lead product is expected to enter the clinic in 2013 in LHON patients. The co-founder and CEO of GenSight, Bernard Gilly, explains why ophthalmology is one of the most best indications for gene therapies: "It is promising because of the safety and efficacy demonstrated in certain trials in this field." Other advantages for GenSight are its "unique, proprietary approach to targeting the mitochondria in LHON developed at the Vision Institute in Paris", and  – Gilly adds – "the exclusive access to key intellectual property from Novartis for using optogenetics to treat RP patients."

The new therapy would enter an anbandoned field as the MAA of Santhera’s synthetic coenzyme Q10 derivative Raxone had to be withdrawn due to EMA concerns only in early 2013.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-02/gene-therapy-enters-the-eye.html

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

BusinessPolandUK

01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • METABOLIC EXPLORER (F)2.26 EUR17.10%
  • CERENIS THERAPEUTICS HOLDING SA (F)8.09 EUR7.72%
  • MOLMED (I)0.42 EUR7.69%

FLOP

  • PHOTOCURE (N)46.40 NOK-8.12%
  • VERNALIS (UK)43.00 GBP-4.44%
  • E-THERAPEUTICS (UK)11.75 GBP-4.08%

TOP

  • DIAMYD MEDICAL -B- (S)7.05 SEK64.0%
  • KARO BIO (S)38.30 SEK28.5%
  • VALNEVA (F)2.89 EUR26.2%

FLOP

  • BIONOR PHARMA (N)0.47 NOK-23.0%
  • NOVOZYMES (DK)284.10 DKK-14.1%
  • RENEURON (UK)2.75 GBP-12.7%

TOP

  • KARO BIO (S)38.30 SEK2387.0%
  • NICOX (F)10.33 EUR455.4%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%

FLOP

  • BB BIOTECH (D)46.45 EUR-81.8%
  • EVOCUTIS (UK)0.04 GBP-78.9%
  • NOVACYT (F)1.30 EUR-71.7%

No liability assumed, Date: 24.08.2016